Stablepharma selected to be part of Innovate UK’s Scaleup Programme
Stablepharma are delighted to announce that they have been selected to be part of Innovate UK’s prestigious Scaleup Programme, recognising the company's potential to grow exponentially and scale globally.
The Scaleup Programme is provided by Innovate UK Business Growth, the innovation agency’s national business growth and scaling service, which supports businesses to grow and become highly successful through coaching and mentorship.
The Programme is designed to support highly innovative, ambitious, high-growth-oriented companies already on their scaling journey, whose innovations or business models can disrupt an existing market, and who are establishing or already implementing their international markets strategy. The companies are selected following a rigorous three-stage screening process.
Stablepharma’s technology platform, StablevaX™ has the ability to convert biopharmaceuticals, vaccines and diagnostic products into fridge-free forms that do not require refrigeration. Stablepharma's technology greatly extends the shelf life of the product, and reduces the need for the unreliable global cold chain, thereby reducing CO2 emissions and minimises vaccine wastage.
Özgür Tuncer, CEO & Executive Director of Stablepharma said:
This is fantastic news for Stablepharma and we are very grateful indeed to be part of this Innovate UK Scaleup Programme. As the programme is based on providing us with tailored support to progress our milestones more rapidly over the next 12 to 18 months, we are really looking forward to engaging with the Scaleup Directors assigned to us.
The Programme features a board of ‘Scaleup Directors’ who provide a matrix of skills and connectivity across multiple domains including M&A, international markets, IP, supply chains, scale-up leadership and talent management.
Nick Child, VP & Co-Founder, said:
The timing could not be better for Stablepharma as we are on the cusp of some exciting milestones in our business. The global problem we are addressing is that vaccines are thermally unstable products that lose their effectiveness if exposed to temperatures which are either too hot or too cold, including mRNA type vaccines, (used during the Covid Pandemic) which require very low storage up to -80°C. Our technology removes the need for refrigeration/cold chain, greatly extending shelf-life of the products and enabling stockpiling. As I said, the timing is ideal.
Stablepharma has a pipeline of thermostable vaccines and technologies that have progressed from early research into full development, including SPVX02, an Adult Booster vaccine for the prevention of Tetanus & Diphtheria (Td), SPVX06, a vaccine for the prevention of Tetanus (TT) and Thermostable RNA-LNP based vaccines. These projects align with Stablepharma's commitment to positively impact global health, and the company aims through partnerships with other European vaccine manufacturers, to expand its portfolio.
Stablepharma has exclusive supply and worldwide commercialisation rights to all products in its pipeline.
